BioSpace News Archive

Applied Molecular Transport Inc. announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the company.

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2022 financial results and provided a business update.

McKesson Corporation will release its fourth-quarter and full-year fiscal 2023 financial results after market close on Monday, May 8, 2023.

Cytonus Therapeutics, Inc. has expanded its Scientific Advisory Board with the appointment of Michael Houston, PhD, former Chief Scientific Officer of TriLink the leading mRNA Contract Research Organization.

CANbridge Pharmaceuticals, Inc. (1228.HK) announced that the CAN008 (asunercept) Phase 2 trial for the treatment of glioblastoma multiforme (GBM) in China is fully enrolled, with a total of 117 patients.

As previously announced on March 21, 2023, Zura Bio Limited (“Zura”) announced the closing of its business combination with JATT Acquisition Corp (“JATT”).

The AIDS Clinical Trials Group (ACTG), the world’s largest HIV research network, is announcing the publication of “Perspectives on Adherence from the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach with 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment” in the journal Clinical Infectious Diseases.

KromaTiD, a single-cell analysis life science tools company focused on the research, development, and commercialization of technology solutions for the cell and gene therapy market, today announced the launch of the dGH in-Site™ CAR-T Kit.

Bryn Pharma LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, announced today that James “Jim” Borneman has been named Chief Operating Officer, effective immediately.